

# Peter Kowey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1047709/publications.pdf>

Version: 2024-02-01

139  
papers

8,286  
citations

76326

40  
h-index

48315

88  
g-index

140  
all docs

140  
docs citations

140  
times ranked

9320  
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 381, 1909-1917.	27.0	1,100
2	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1261.	7.4	953
3	Dronedaron for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. <i>New England Journal of Medicine</i> , 2007, 357, 987-999.	27.0	597
4	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2597-2604.	2.8	401
5	The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, ehv476.	2.2	316
6	Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. <i>American Heart Journal</i> , 2019, 207, 66-75.	2.7	311
7	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494.	1.6	224
8	Patients'™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	2.7	211
9	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population. <i>JAMA Cardiology</i> , 2017, 2, 1120.	6.1	200
10	Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2363.	7.4	183
11	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. <i>JAMA Cardiology</i> , 2016, 1, 282.	6.1	182
12	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 393-402.	2.2	173
13	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	2.7	161
14	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	143
15	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. <i>American Heart Journal</i> , 2011, 162, 606-612.e1.	2.7	137
16	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2014, 167, 601-609.e1.	2.7	135
17	The HARMONY Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1048-1056.	4.8	129
18	Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1325-1335.	2.8	124

#	ARTICLE	IF	CITATIONS
19	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 167, 735-742.e2.	2.7	120
20	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 168, 487-494.	2.7	107
21	Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches. <i>American Journal of Cardiology</i> , 2003, 91, 33-38.	1.6	106
22	Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. <i>Chest</i> , 2013, 144, 758-765.	0.8	95
23	Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2017, 5, 44-52.	4.1	91
24	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. <i>Heart Rhythm</i> , 2017, 14, e41-e44.	0.7	91
25	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. <i>American Heart Journal</i> , 2016, 174, 29-36.	2.7	82
26	A Broken Heart. <i>Circulation</i> , 1998, 98, 1349-1349.	1.6	77
27	Association of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	6.1	77
28	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 2005-2012.	1.6	73
29	Clinical Outcome of Patients Who Develop PAF After CABG Surgery. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 191-193.	1.2	71
30	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , 2014, 168, 160-167.	2.7	62
31	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005358.	2.2	59
32	Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 315-322.	3.2	53
33	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017, 189, 40-47.	2.7	53
34	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 896-904.	2.2	52
35	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1.	1.5	49
36	Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). <i>American Journal of Cardiology</i> , 2010, 105, 1122-1129.	1.6	45

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. <i>Circulation</i> , 2011, 124, 2649-2660.	1.6	45
38	Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 355-363.	3.2	45
39	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. <i>Journal of Thoracic Disease</i> , 2015, 7, 165-71.	1.4	44
40	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). <i>Circulation</i> , 2017, 135, 1000-1008.	3.7	44
41	Acquired long QT syndrome in hospitalized patients. <i>Heart Rhythm</i> , 2017, 14, 974-978.	0.7	42
42	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, e002031.	3.7	41
43	Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. <i>Journal of the American Heart Association</i> , 2016, 5, e002944.	3.7	37
44	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the REVERA Study). <i>Journal of Cardiology</i> , 2017, 119, 1590-1595.	1.6	33
45	Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. <i>American Heart Journal</i> , 2014, 167, 22-27.	2.7	32
46	Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologists (from the AFFECTS Study). <i>Journal of the American Heart Association</i> , 2017, 6, e007303.	1.6	30
47	Heterogeneous distribution of INa-L determines interregional differences in rate adaptation of repolarization. <i>Heart Rhythm</i> , 2015, 12, 1295-1303.	0.7	30
48	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	29
49	Update on atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 14-25.	4.9	29
50	Cardiovascular Safety During and After Use of Phentermine and Topiramate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 513-522.	3.6	28
51	Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. <i>Heart Rhythm</i> , 2016, 13, 1777-1783.	0.7	27
52	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	4.8	27
53	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 449-456.	1.5	25
54	Disease understanding in patients newly diagnosed with atrial fibrillation. <i>Heart</i> , 2018, 104, 494-501.	2.9	25

#	ARTICLE	IF	CITATIONS
55	Ambulatory Electrocardiographic Recording. <i>Circulation</i> , 2003, 108, e31-3.	1.6	23
56	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 889-897.	1.6	23
57	Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e010063.	4.8	23
58	COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. <i>Heart Rhythm</i> , 2015, 12, 1105-1112.	0.7	22
59	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019, 105, heartjnl-2018-313642.	2.9	22
60	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495.	2.7	21
61	Antiarrhythmic Drug Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 205-221.	2.1	21
62	Effect of the 2014 Atrial Fibrillation Guideline Revisions on the Proportion of Patients Recommended for Oral Anticoagulation. <i>JAMA Internal Medicine</i> , 2015, 175, 848.	5.1	20
63	Status of Antiarrhythmic Drug Development for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e002479.	4.8	20
64	A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 21-28.	3.0	20
65	Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation. <i>Drugs in R and D</i> , 2011, 11, 1-11.	2.2	19
66	ST Segment Elevation and Sudden Cardiac Death: From the Brugada Syndrome to Acute Myocardial Ischemia. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 1330-1332.	1.7	18
67	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. <i>American Heart Journal</i> , 2017, 185, 59-66.	2.7	18
68	Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?. <i>World Journal of Cardiology</i> , 2014, 6, 764.	1.5	18
69	Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT- $\text{\textcircled{A}}$ AF I) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	16
70	Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey. <i>Clinical Cardiology</i> , 2010, 33, 172-178.	1.8	13
71	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2016, 181, 145-152.	2.7	13
72	Emboic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1677-1683.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2020, 226, 85-93.	2.7	13
74	The Role of Dronedaron in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS. Current Cardiology Reviews, 2014, 10, 303-308.	1.5	13
75	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. Journal of the American Heart Association, 2018, 7, .	3.7	12
76	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. American Heart Journal, 2020, 219, 128-136.	2.7	12
77	Device Interaction-Antitachycardia Pacemakers and Defibrillators for Sustained Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 302-307.	1.2	10
78	Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. American Heart Journal, 2017, 185, 43-51.	2.7	10
79	Cardiovascular Safety of the Selective $\mu$ -Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 309-317.	2.0	10
80	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	6.1	10
81	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	2.7	10
82	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
83	AIM-AF: A Physician Survey in the United States and Europe. Journal of the American Heart Association, 2022, 11, e023838.	3.7	10
84	Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome. American Journal of Cardiology, 2014, 113, 888-896.	1.6	9
85	Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 747-754.	4.8	9
86	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 435-439.	2.1	9
87	Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke, 2021, 52, 2715-2722.	2.0	9
88	Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010204.	4.8	8
89	The Silent Majority. JAMA - Journal of the American Medical Association, 2011, 306, 18-9.	7.4	7
90	The impact of medical malpractice litigation on cardiovascular practice in the US and China. International Journal of Cardiology, 2014, 177, 48-50.	1.7	7

#	ARTICLE	IF	CITATIONS
91	Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017. <i>Heart Lung and Circulation</i> , 2017, 26, 926-933.	0.4	7
92	Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. <i>International Journal of Cardiology</i> , 2019, 274, 152-157.	1.7	7
93	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. <i>Journal of Atrial Fibrillation</i> , 2017, 9, 1551.	0.5	7
94	Antiarrhythmic Drug Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 533-549.	2.2	6
95	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124.	1.6	6
96	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. <i>Clinical Cardiology</i> , 2016, 39, 119-125.	1.8	6
97	Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). <i>American Journal of Cardiology</i> , 2017, 119, 47-51.	1.6	6
98	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	6
99	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007775.	4.8	6
100	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	2.2	5
101	Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the <i>Sclerochitin ilicifolius</i> plant. <i>Food and Chemical Toxicology</i> , 2016, 91, 217-224.	3.6	4
102	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). <i>American Journal of Cardiology</i> , 2019, 124, 864-870.	1.6	4
103	Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review. <i>Heart Lung and Circulation</i> , 2019, 28, 49-56.	0.4	4
104	The Relentless Pursuit of New Drugs to Treat Cardiac Arrhythmias. <i>Circulation</i> , 2020, 141, 1507-1509.	1.6	4
105	Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. <i>Cardiology</i> , 2021, 146, 633-640.	1.4	4
106	Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 0, , 1-15.	0.8	4
107	Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia. <i>Clinical Cardiology</i> , 2000, 23, 171-174.	1.8	3
108	Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator. <i>Arrhythmia and Electrophysiology Review</i> , 2019, 8, 99-104.	2.4	3

#	ARTICLE	IF	CITATIONS
109	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	2.7	3
110	Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart, 2021, 107, 642-649.	2.9	3
111	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. American Journal of Cardiology, 2021, 145, 64-68.	1.6	3
112	How Much Has Malpractice Litigation Altered the Care of Cardiac Rhythm Patients?. Journal of Cardiovascular Electrophysiology, 2011, 22, 488-489.	1.7	2
113	The Evolution of the One-Armed Bandit. Journal of the American College of Cardiology, 2019, 74, 2376-2378.	2.8	2
114	Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. Heart Rhythm, 2021, 18, 2177-2186.	0.7	2
115	Monomorphic Right Ventricular Tachycardia in a Patient with Mitral Valve Prolapse. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 509-513.	1.2	1
116	Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician. European Heart Journal, 2015, 36, 265-266.	2.2	1
117	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS and ADONIS trials. Clinical Cardiology, 2022, 45, 101-109.	1.8	1
118	I've Fallen and I Can't Get Up. The American Journal of Geriatric Cardiology, 2003, 12, 306-306.	0.6	0
119	Cardiac Implantable Electrical Devices in the Elderly: A Promise of Prolonged Survival and an Improved Quality of Life. The American Journal of Geriatric Cardiology, 2006, 15, 75-76.	0.6	0
120	Why Did You Order That Echocardiogram?. Clinical Cardiology, 2010, 33, 596-597.	1.8	0
121	In Memoriam Tribute to Dusan Z. Kocovic, MD. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 990-990.	4.8	0
122	Smoothing the Bumpy Road to Antiarrhythmic Drug Development. Circulation, 2015, 132, 2195-2197.	1.6	0
123	Observing the Obvious— . Journal of the American College of Cardiology, 2015, 66, 1008-1010.	2.8	0
124	Darned If You Do—   Darned If You Don't. Journal of Cardiovascular Electrophysiology, 2016, 27, 811-812.	1.7	0
125	Glass Half Empty? —. JACC: Clinical Electrophysiology, 2016, 2, 782-783.	3.2	0
126	Back to the basics. Heart Rhythm, 2017, 14, 455-456.	0.7	0



#	ARTICLE	IF	CITATIONS
127	The tyranny of numbers, large and small. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1443-1444.	1.7	0
128	Assessing intracardiac thrombus prior to cardioversion: A story yet to be told. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 548-550.	1.7	0
129	Atrial Fibrillation Ablation Should Be First-Line Therapy in Heart Failure Patients: CON. <i>Cardiology Clinics</i> , 2019, 37, 197-206.	2.2	0
130	Cardioversion of obese patients: What is the weight of evidence?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 162-163.	1.7	0
131	A most remarkable person: Dr Bernard Lown. <i>European Heart Journal</i> , 2021, 42, 1938-1939.	2.2	0
132	Corroboration equals collaboration. <i>Heart Rhythm</i> , 2021, 18, 682-683.	0.7	0
133	Cherry-picking atrial fibrillation ablation responders: Can antiarrhythmic drugs help?. <i>Heart Rhythm</i> , 2021, 18, 1480-1481.	0.7	0
134	Medicine on Twitter. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009434.	4.8	0
135	Should Physicians Continue to Recommend Fish Oil for Patients with Atrial Fibrillation?. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 593.	0.5	0
136	Abstract 15742: An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner. <i>Circulation</i> , 2020, 142, .	1.6	0
137	Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events. <i>Circulation</i> , 2020, 142, .	1.6	0
138	Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. <i>Clinical Cardiology</i> , 2022, 45, 119-128.	1.8	0
139	Increased susceptibility to ventricular arrhythmia at low-normal and moderately-low levels of extracellular potassium in Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Heart Rhythm</i> , 2022, , .	0.7	0